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Abstract 
Review on EGR1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: AT225, G0S30, KROX-24, NGFI-
A, TIS8, ZIF-268, ZNF225 
HGNC (Hugo): EGR1 
Location: 5q31.2 
DNA/RNA 
Note 
The gene is conserved in chimpanzee, dog, cow, 
mouse, rat, chicken, and zebrafish. 
Description 
Genomic size 3824 bp; 2 exons; + strand of 
chromosome 5. 
Transcription 
mRNA size: 3132, ORF 271-1902 (1632 nt coding 
sequence). 
Rare occurrence of splice variants (2 variants have 
been described in the brain).  
The EGR1 promoter contains five SREs (serum 
response elements). Increased transcription in 
response to growth factors or stress is most 
commonly mediated by transcription factors of the 
Elk-1/SAP-1/SAP-2 family, which are activated by 
MAP-Kinase family (mitogen activated protein 
kinase). Elk-1 associates with CBP (CREB binding 
protein) and SRF (serum response factor) to form 
the Ternary Complex Factor, which binds to the 
SREs. 
The promoter also contains several SP1 consensus 
sequences; a putative AP-1 binding site (not 
conserved); at least one functional CRE (cAMP 
regulatory element). EGR1 regulates its own 
transcription by binding to functional EBS (EGR1 
binding sites). A functional NFkB (p65/RelA) 
binding site is contained in the EGR1 promoter that 
allows NF-kB to increase EGR1 transcription in 
response to UV (ultra-violet) irradiation. EGR1 is a 
target of ETS transcription factors that are involved 
in hematopoiesis, angiogenesis and neoplasia. 
Finally, EGR1 promoter contains two ATF5 
(activating transcription factor 5) consensus 
sequences at a conserved promoter position and is 
induced by ATF5 in cancer cell lines. 
Protein 
Description 
The protein contains 543 amino acids. Its predicted 
molecular weight is 57.5 kDa, however the protein 
migrates at an apparent molecular weight of 75-85 
kDa in SDS-PAGE. It has a very short half-life of 
~30 minutes to 1 hour. 
EGR1 contains a highly conserved DNA-binding 
domain composed of three Cys2-His2 type zinc-
fingers that bind to the prototype target sequence 
GCG(G/T)GGGCG; a nuclear localization signal 
that requires amino acids 361-419 (zinc fingers 2 
and 3) and amino acids 315-330; two activator 
domains; a repressor domain between amino acids 
281-314.  
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Figure 1. 
 
EGR1 binds to regulatory proteins called NAB-1 
(NGFA-I binding protein) and NAB2 through its 
repressor domain. 
Post-translational modifications include 
phosphorylation, acetylation, ubiquitination and 
sumoylation (figure 1). 
Expression 
Ubiquitous. Exhibits a distinct expression pattern in 
the brain. Constitutive protein expression is low in 
many tissues. EGR1 expression is very rapidly and 
strongly induced by growth factors and mitogens, 
cytokines, environmental and mechanical stresses, 
as well as DNA damage (hpr). 
Localisation 
Nuclear. Occasional cytoplasmic localization 
observed in cancer cells. 
Function 
EGR1 is an early response transcription factor with 
DNA binding activity that activates the 
transcription of several hundred genes. Depending 
on the cell type and the stimulus, EGR1 induces the 
expression of growth factors, growth factor 
receptors, extracellular matrix proteins, proteins 
involved in the regulation of cell growth or 
differentiation, and proteins involved in apoptosis, 
growth arrest, and stress responses. 
EGR1 can compete with transcription factor SP1, 
which is involved in the constitutive expression of 
housekeeping genes and other regulatory genes. 
Because the consensus sequence for SP1 and EGR1 
binding overlaps, EGR1 often displaces SP1 from 
gene promoters. 
EGR1 transcriptional activity is inhibited by direct 
interaction with the proteins NAB1 and NAB2. 
Their expression is also inducible, albeit delayed 
compared to EGR1 induction. NAB1 and NAB2 
impose an early negative feedback and thus ensure 
that EGR1 activity is transient, before the protein is 
degraded. It should be noted that deregulated 
expression of NAB proteins in disease may 
contribute to alteration of EGR1 function. For 
example, elevated expression of NAB2 in 
endothelial cells reduces angiogenesis, whereas loss 
of NAB2 in prostate cancer contributes to increased 
EGR1 activity. 
EGR1 has various neurocognitive functions. It is 
involved in the regulation of neuronal activity and 
may control neuronal plasticity. EGR1 controls 
tissue repair, wound healing, liver regeneration, 
atherosclerosis, fibrosis, and other inflammation or 
stress-related responses. It is considered a key 
master regulator in cardiovascular pathology by 
promoting atherosclerosis, intimal thickening 
following vascular injury, ischemia, allograft 
rejection and cardiac hypertrophy. Finally, EGR1 
regulates cell response to hypoxia, promotes the 
formation of new blood vessels from the pre-
existing vasculature, and triggers tumor 
angiogenesis. 
In cancer, EGR1 is traditionally considered a tumor 
suppressor. However, accumulating evidence now 
indicates that it can act both as a tumor suppressor 
and as a tumor promoter, depending on the context. 
EGR1 protects normal cells from transformation by 
inducing apoptosis or growth arrest upon DNA 
damage. A strong evidence for EGR1 pro-apoptotic 
function is that EGR1-/- mouse embryo fibroblasts 
are resistant to apoptosis induced by ionizing 
radiation. Although EGR1-deficient mice do not 
spontaneously develop tumors, they display 
accelerated tumor growth in a two-step 
carcinogenesis model of skin cancer. As an 
example, UV-B radiation of keratinocytes induces 
EGR1 expression through activation of NFkB 
(p65/RelA), which mediates apoptosis and acts as a 
protection mechanism against the tumorigenic 
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effect of UV. These observations support the notion 
that EGR1 participates in the suppression of DNA 
damage-induced tumors. 
EGR1 is involved in the chemopreventive or 
antiproliferative effect of natural compounds such 
as curcumin, genistein, isoflavone, green tea 
extracts, and others. It also mediates the anti-
proliferative effects of NSAIDs (non-steroid anti-
inflammatory drug) and of other chemotherapeutic 
agents such as cisplatin. 
In many cancer cells, EGR1 is induced by radiation, 
chemotherapeutic drugs, steroids and anti-
inflammatory drugs, and is required for the growth 
arrest or apoptotic effect of these treatments. Lack 
of EGR1 response confers chemoresistance. This 
may be exploited by restoring EGR1 expression 
through gene therapy to increase the efficacy of 
radiotherapy of chemotherapy. 
At later stages of cancer EGR1 tumor suppressor 
function is impaired by the frequent inactivation, in 
human tumors, of two major tumor suppressor 
targets of EGR1 (namely PTEN and TP53). In 
addition, EGR1 induction by growth factors or 
stress is blocked in some types of cancer cells 
("resistance" to induction). This has been described 
in fibrosarcoma, prostate cancer, colon cancer, and 
RAS-transformed cells. Several mechanisms are 
involved. For example, RAS-induced 
transformation of fibroblasts results in the aberrant 
constitutive activation of PI3-kinase (phosphatidyl 
inositol 3-kinase), which causes degradation of SRF 
and prevents Elk-1-mediated induction of EGR1. In 
colon cancer cells, it is the mutational activation of 
Wnt-1 that prevents the SRF-mediated induction of 
EGR1 and other early genes in response to 
mitogens. Alternatively, overexpression of 
phospholipase D in glioma cells attenuates 
mitogen-induced EGR1 expression through 
activation of PI3-kinase. 
On the other hand, EGR1 overexpression in some 
cancer types directly promotes cancer progression 
and tumor growth by increasing the expression and 
secretion of growth factors and cytokines, 
extracellular matrix proteins (Barbolina et al., 2007; 
Shin et al., 2010) and proteases. Egr-1 mediates 
growth factor-induced downregulation of E-
cadherin by inducing an E-cadherin transcription 
repressor, Snail or Slug, which contributes to tumor 
invasion (Grotegut et al., 2006; Cheng et al., 2013). 
Mechanisms that can cause EGR1 overexpression 
in tumor cells include p53 mutations (observed in 
gliomas and prostate cancer). Mutant p53 
upregulates EGR1 in prostate cancer cells by 
activating ERK (extracellular regulated kinase) 
through undefined mechanism. Constitutive 
activation of the ERK pathway in tumor cells 
appears to be a consistent cause of EGR1 
expression and is often due to genetic defects 
affecting upstream regulators of the ERK pathway. 
For example, a mutation of EGFR (epidermal 
growth factor receptor) commonly found in lung 
cancer cells causes EGR1 overexpression and 
activation through activation of the ERK pathway. 
Similarly, a mutation of B-RAF present in a high 
percentage of melanoma results in constitutive 
activation of ERK and up-regulation of EGR1. 
Homology 
Three other family members: EGR2, EGR3 and 
EGR4 (see figure 2). 
 
Figure 2. Image designed by Melody W Lin. 
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Mutations 
Note 
Mutations in the EGR1 gene have not been found; 
altered expression level is the most common 
contributor to tumorigenesis. 
Chromosome loss/deletions:  
- The long arm of chromosome 5 in which EGR1 is 
located is consistently deleted in myelodysplastic 
syndrome (MDS) and acute myeloid leukemia 
(AML). Loss of chromosome 5 or deletion in 5q is 
the most common karyotypic abnormality in MDS, 
occurring in 10% of new MDS/AML patients and 
in 40% of patients with therapy-related MDS or 
AML. Mice lacking at least one allele of EGR1 
develop symptoms similar to that of MDS after they 
are exposed to a carcinogen (i.e. mono- or bi-allelic 
loss of EGR1 accelerates the development of pre-
leukemic disorders). 
- Loss of 5q is consistently associated with estrogen 
receptor-negative (ER-) breast carcinoma and is 
seen in 86% of breast carcinomas carriers of 
BRCA1 (breast cancer 1) and BRCA2 mutations. 
Fluorescence in situ hybridization confirmed the 
association of EGR1 loss with ER- breast 
carcinoma; loss of EGR1 correlated with high 
grade. 
- In mouse model with a deletion of chromosome 5, 
loss of Tp53 activity in cooperation with EGR1 and 
adenomatous polyposis coli (APC) 
haploinsufficiency, accelerates the development of 
AML (Stoddart et al., 2013). 
Implicated in 
Various cancers 
Note 
EGR1 (protein and/or mRNA) is downregulated in 
colon cancer, lung cancer, esophageal carcinoma, 
astrocytomas, glioblastomas, breast cancer, 
compared to non-cancer tissue. EGR1 expression is 
sharply decreased in leiomyoma compared to 
normal myometrium (reduction in 100% of 
tumors).  
Transfection of EGR1 into myometrial cells 
decreases cell proliferation. 
In some types of cancers EGR1 expression is high 
in the adjacent tissue of the tumors, but low in the 
tumor cells. In esophageal carcinoma, EGR1 
expression is higher in the dysplastic tissue, 
whereas no expression is detected in the tumor 
tissue. This may reflect the existence of a reactive 
stroma, and possibly inflammation.  
Early observations indicated that in v-sis-
transformed NIH-3T3 cells, transfection of EGR1 
inhibits colony formation and growth in soft agar. It 
also delays tumorigenicity in nude mice. 
Conversely, EGR1 antisense accelerates cell growth 
and colony formation.  
EGR1 expression is upregulated in human diffuse 
large B cell lymphoma because of constitutively 
active ERK and JNK (Jun N-terminal kinase) 
pathways and promotes cancer cells survival. 
Overexpression of EGR1 (both mRNA and protein) 
is observed in gastric cancer and in prostate cancer. 
It is also seen in the "normal" tissue adjacent to the 
tumors, but it is not expressed in the normal tissues 
from healthy patients. The mRNA expression is 
higher in metastatic cases of gastric cancer. EGR1 
is much higher expressed in cervical cancer tissues 
than in the normal cervix. 
Leukemia 
Note 
In myeloblastic leukemia, upregulation of oncogene 
E2F-1 blocks the myeloid terminal differentiation 
program, resulting in proliferation of immature 
cells in the presence of interleukin-6. EGR1 
abrogates the E2F-1-driven block in myeloid 
terminal differentiation, decreases the tumorigenic 
potential of leukemia cells in vivo and their 
aggressiveness. EGR1 also abrogates the block in 
terminal myeloid differentiation imparted by 
oncogenic c-myc. 
Fibrosarcoma 
Note 
Human fibrosarcoma cells express almost no EGR1 
and are "resistant" to EGR1 induction in response 
to growth factors or stress. Forced expression of 
EGR1 inhibits cell growth and suppresses xenograft 
tumor growth in athymic mice. Conversely, 
silencing EGR1 using antisense increases the 
transformed character of these cells. 
The effect of EGR1 in HT-1080 fibrosarcoma cells 
is mediated by increased secretion of active 
TGFbeta-1 (transforming growth factor-beta1), a 
direct target of EGR1. TGFbeta-1 strongly inhibits 
cell growth in an autocrine mechanism. Further, 
EGR1 regulates cell adhesion and migration 
through increased secretion of fibronectin and 
plasminogen activator inhibitor-1 (PAI-1). 
Although fibronectin is a direct target of EGR1, 
PAI-1 increase is mediated by EGR1-induced 
TGFbeta-1. 
Lung cancer 
Note 
EGR1 (RNA and protein) is expressed at higher 
levels in human normal lung tissue adjacent to non-
small cell lung cancer (NSCLC), and is 
downregulated in the tumor tissue compared with 
normal lung. Also downregulated in human lung 
adenocarcinomas and lung squamous cell 
carcinomas. 
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High expression of EGR1 in NSCLC patients 
correlates with high PTEN expression. Low levels 
of EGR1 after surgical resection are associated with 
poor outcome. 
Brain cancer 
(astrocytoma/glioblastoma/neuroblas
toma) 
Note 
EGR1 mRNA and protein are strongly suppressed 
in astrocytomas and glioblastomas compared to 
normal brain. Downregulation correlates with grade 
in human tissue, or with the presence of wild-type 
p53 in cell cultures.  
Tumors or primary cell lines that exhibit higher 
EGR1 expression contain p53 mutations. EGR1 
induces growth arrest of glioma cells mediated by 
increased secretion of TGF-beta1, PAI-1 and 
fibronectin. EGR1 expression is induced by 
hypoxia in glioblastoma multiforme and up-
regulates tissue factor that promotes plasma 
clotting. 
Two EGR1 mRNA variants are detected in 
astrocytomas, one that contains N-methyl-D-
aspartate-receptor (NMDA-R)-responsive element. 
An increase in the expression of this EGR1 variant 
is seen in astrocytoma cells following NMDA 
stimulation. EGR1 expression is restricted to tumor 
cells expressing NMDA-R, is up-regulated in 
astrocytomas compared with normal brain, and is 
associated with enhanced patient survival.  
In neuroblastoma cells, re-expression of EGR1 
induces apoptosis, whereas EGR1 antisense 
increases cell viability. The apoptotic activity of the 
EGR1 is mediated by activation of p73 (a member 
of the p53 family). 
Breast cancer 
Note 
Breast cancer cell lines and clinical cancer tissues 
exhibit reduced EGR1 expression while normal 
mammary tissues express high levels. EGR1 is also 
downregulated in experimentally induced rat 
mammary tumors. Downregulation of gelsolin, 
which is an indicator of breast cancer, is correlated 
with suppression of EGR1.  
Some studies have shown that re-expression of 
EGR1 inhibits human tumor cell growth and 
suppresses tumorigenicity in mice. However, two 
other studies found that EGR1 silencing decreases 
breast cancer cell proliferation, migration, and 
growth of xenograft tumors in nude mice.  
In estrogen receptor-positive breast cancer cell 
lines, EGR1 expression is induced by estrogen 
through activation of RAF-1 kinase, the MAP-
kinase pathway, and Elk-1/SRF. 
Hepatocellular carcinoma (liver 
cancer) 
Note 
While one study reports EGR1 overexpression, 
another one describes the downregulation of EGR1 
expression in hepatocellular carcinoma. In the latter 
study, re-expression of EGR1 decreased cell growth 
and tumorigenicity in nude mice.  
There are arguments in favor of a pro-tumorigenic 
function: HGF (hepatocyte growth factor), a 
cytokine involved in the progression of 
hepatocarcinoma, up-regulates EGR1 and increases 
cell scattering and migration through EGR1-
mediated up-regulation of snail. HGF also increases 
angiogenesis through up-regulation of EGR1-
mediated VEGF (vascular endothelial growth 
factor) and interleukin 8. Of note, EGR1 is crucial 
for the proliferation of hepatocytes and plays an 
important role in liver regeneration: liver 
regeneration following partial hepatectomy is 
impaired in EGR1-null mice. 
Skin cancer/melanoma 
Note 
EGR1 expression is decreased in basal cell 
carcinoma (BCC) and squamous cell carcinoma 
(SCC) but is elevated in psoriasis. EGR1 inhibits 
the growth of benign and malignant epidermal cells 
in vitro.  
A single topical treatment with the tumor promoter 
TPA in a multistage carcinogenesis model induces 
EGR1 mRNA expression both epidermis and 
dermis of the mice. Primary papillomas and 
carcinomas generated in these animals contain high 
EGR1 mRNA compared with normal epidermis. 
EGR1-null mice reveal an accelerated development 
of skin tumors in the multistage carcinogenesis 
model compared to EGR1+ mice.  
On the other hand, EGR1 may contribute to cancer 
progression in melanoma. The HGF receptor c-Met 
induces EGR1 activation via the Ras/ERK1/2 
pathway in melanoma cells, which in turn induces 
fibronectin expression and its extracellular 
assembly. Fibronectin promotes migration and 
invasiveness of melanomas and is associated with 
metastatic potential.  
About 60% of melanoma contain an activating 
mutation in the B-RAF gene. In these cells, 
constitutive up-regulation of EGR1 caused by 
activation of RAF/ERK signaling results in high 
fibronectin levels and increases invasiveness. 
Prostate cancer 
Note 
EGR1 mRNA is expressed at higher levels in 
prostate tumors compared with normal tissues and  
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correlates with Gleason score (a measure of prostate 
cancer stage). EGR1 expression in the primary 
tumor correlates with complete control of the local 
tumor by radiation, whereas in post-irradiated tissue 
EGR1 expression correlates with treatment failure. 
NAB2 is down-regulated in clinical primary 
carcinoma. Thus, upregulation of EGR1 and loss of 
NAB2 both determine the high level of EGR1 
activity in human prostate tumors. 
EGR1 knock-out mice crossed with transgenic 
mouse models of prostate cancer show significantly 
impaired tumor growth compared to Egr+/+ mice 
and increased survival. Although it does not prevent 
tumor initiation, EGR1 deficiency delays the 
progression of prostate carcinoma. EGR1 is also 
overexpressed in the tumors of the transgenic mice, 
whereas NAB2 expression is decreased.  
Silencing of EGR1 in prostate cancer cells 
decreases cell proliferation in vitro, and injection of 
EGR1 antisense in vivo delays the occurrence of 
prostate cancer. Alternatively, forced expression of 
EGR1 in non-cancer cells increases proliferation in 
vitro.  
EGR1 up-regulation in prostate cell lines is due to 
mutation of the TP53 gene. EGR1 is also up-
regulated by SV40-T antigen, a viral oncogene that 
is used very often to immortalize non-transformed 
cells. In human prostate cancer cells EGR1 
stimulates the production of many growth factors 
and cytokines that are involved in the progression 
of prostate cancer and of proteins involved in 
metastasis. 
A crosstalk between EGR1 and the androgen 
receptor (AR) may explain the particular role of 
EGR1 in prostate cancer. EGR1 physically interacts 
with AR in hormone-sensitive prostate cancer cells 
and the complex binds to the promoter of 
endogenous targets of AR. Forcing EGR1 activity 
in hormone-sensitive cancer cells increases 
proliferation in vitro. It enhances tumor growth in 
mice upon castration (which mimics hormone 
therapy in human patients): EGR1 may be involved 
in the acquisition of resistance to hormone therapy. 
Esophageal carcinoma 
Note 
According to some reports, the expression of EGR1 
(mRNA and protein) is high in pre-cancerous 
human lesions of the esophagus and in dysplastic 
tissue adjacent to esophageal carcinoma, but is very 
low in cancer tissue. The number of apoptotic cells 
in EGR1-positive tumors is higher than in EGR1 
negative tumors, suggesting that EGR1 promotes 
apoptosis. In addition, EGR1 is up-regulated in the 
tumors of patients treated by irradiation compared 
to the tumor tissue of non-irradiated patients, and 
EGR1 expression level seems to correlate with 
better prognosis. 
Another study, however, shows overexpression of 
EGR1 in esophageal tumor tissues and constitutive 
expression in esophageal cancer cell lines.  
EGR1 silencing inhibits cell proliferation through 
G2/M cell cycle block. On the other hand, forced 
stable expression of EGR1 into esophageal 
carcinoma cells also decreases cell proliferation in 
vitro and tumor growth in vivo. 
Cervical cancer 
Note 
The melanoma growth stimulatory activity/Growth-
regulated oncogene α (MGSA/GROα), which is 
designated as a CXC chemokine ligand 1 (CXCL1), 
plays an important role in the regulation of 
inflammation and the progression of tumor 
development through stimulation of angiogenesis 
and metastasis. EGR1 mediates ERK and JNK 
MAPKs-dependent GROα transcription in response 
to TNFα stimulation in HeLa cervix cancer cells 
(Shin et al., 2013). 
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